Clinical trials: Respiratory System Disease
Pulmonary Disease, Chronic Obstructive
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
This study is primarily aimed to investigate whether PROs can be improved after the initiation of BGF pMDI in real world clinical settings.
- Trial name
- EBISU (NCT05219630)
- Where
- 17 sites in Japan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
COVID-19
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease
- Trial name
- NCT04869228
- Where
- Brazil
- Volunteers
- 380 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Lung Cancer, Nodes, Lung
Confirmation of Accuracy of the Tool-in-lesion Technology (TiLT) of the Galaxy System With Integrated TOMO Technology
This study will evaluate the feasibility of performing robotic navigation of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
- Trial name
- TiLT (NCT06056128)
- Testing
- Robotic assisted bronchoscopy
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Noah Medical
Seasonal Allergic Rhinitis
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.
- Trial name
- NCT00960141
- Testing
- montelukast sodium, Comparator: loratadine
- Volunteers
- 829 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02233881
- Testing
- Atrovent® - inhalets
- Volunteers
- 4,222 people
- Sponsor
- Boehringer Ingelheim
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
The primary goal of this post marketing surveillance (PMS) study is to document the efficacy of Tiotropium (Spiriva) to improve physical activity measured by a score that is recommended in national chronic obstructive pulmonary…
- Trial name
- NCT00615992
- Testing
- Tiotropium
- Where
- 73 sites in Austria
- Volunteers
- 754 people
- Sponsor
- Boehringer Ingelheim
Influenza
Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation
The main purpose of this study is to assess the potential exposure of neonates to oseltamivir during lactation by examining oseltamivir concentrations in maternal blood, urine, and breast milk in breastfeeding women who are…
- Trial name
- NCT01130636
- Testing
- Oseltamivir
- Where
- 2 sites in Hungary
- Volunteers
- 6 people
- Sponsor
- Pharmahungary Group
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
Currently, several vaccines are available to combat the COVID-19 pandemic. The persistence of SARS-CoV-2 globally requires the development of additional vaccines to aid in preventing further SARS-CoV-2 infections.
- Trial name
- VAX-002-01 (NCT06436911)
- Testing
- COVIGENIX VAX- 002
- Where
- 6 sites in Canada
- Volunteers
- 46 people
- Sponsor
- Entos Pharmaceuticals Inc.
Tonsillitis
Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children
The primary objective of this study is to demonstrate the non-inferiority, at the assessment visit (V3 (D10/D14)), in terms of bacteriological efficacy of pristinamycin (PRI) administered for 4 days versus amoxicillin (AMX)…
- Trial name
- PRI-angine (NCT00393744)
- Testing
- pristinamycin, amoxicillin
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Sanofi
NSCLC Stage IV
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT04633564
- Testing
- Bevacizumab as MYL-1402O, Bevacizumab as Avastin
- Where
- 102 sites in Belarus, Bosnia and Herzegovina and 15 more
- Volunteers
- 671 people
- Sponsor
- Mylan Pharmaceuticals Inc
Locally Advanced Lung Cancer; Metastatic Lung Cancer
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in combination with standard platinum-based chemotherapy in participants with advanced NSCLC or SCLC.
- Trial name
- NCT03432598
- Testing
- Tislelizumab, Paclitaxel, Gemcitabine
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- BeiGene
Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults
Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
- Trial name
- NCT03357263
- Testing
- GC3114, GCFLU Quadrivalent
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Infections, Community Acquired Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Community Acquired Bacterial Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01530763
- Testing
- Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 161 people
- Sponsor
- Forest Laboratories
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Solid Tumors, Pancreatic Cancer
CTS2190 Phase I /II Clinical Study in Patients
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types.
- Conditions
- Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
- Trial name
- NCT06224387
- Testing
- CTS2190 capsules
- Where
- 2 sites in China
- Volunteers
- 224 people
- Sponsor
- CytosinLab Therapeutics Co., Ltd.
Influenza
A Trial of RLX-2508-102 in Healthy Volunteers
The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.
- Trial name
- NCT07873671
- Testing
- RLX-2508
- Where
- 3 sites in Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
COVID-19
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers
- Trial name
- NCT04870164
- Testing
- Ensovibep
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Molecular Partners AG
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06589921
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.